Table 4 Sensitivity analyses
Sensitivity analysis | Description of approach | Change in outcomes evaluated |
|---|---|---|
Per protocol analysis | Exclude participants who did not use the DATs to the end of the treatment period | Cost-effectiveness |
Changes in the number of healthcare visits | Change the number of healthcare visits to resemble what was observed prior to the COVID epidemic to see the impact on costs and cost-effectiveness | Provider and patient costs |
Cost of the DATs | Increase and decrease the cost per person of DATs | Provider costs; cost-effectiveness |
Analytical timeframe | Only include the costs and outcomes incurred during the treatment of trial participants until the end of the trial | Cost-effectiveness |
Catastrophic costs threshold | Varying the catastrophic costs threshold from between 10 and 20% | Patient costs; cost-effectiveness |
Discount rates | Vary the discount rate used for costs and effects from 3 to 0% and 10% | Costs, effects and cost-effectiveness |